The DOI matches its Crossref record; 60 of the 60 references it cites were found in a registry or an index.
Critical Appraisal of Guideline Recommendations on Systemic Therapies for Advanced Hepatocellular Carcinoma: A Review
Open accessAbstract
Importance: The combination of immune checkpoint inhibitors with antiangiogenic agents has revolutionized the treatment landscape of advanced hepatocellular carcinoma (HCC). However, due to rapid publication of new studies that attained their predefined primary end points, a lack of robust cross-trial comparison of first-line therapies, and diverging clinical guidelines, no clear-cut treatment flowchart and sequence of therapies are available. This critical analysis of the recommendations for the management of advanced HCC from the main scientific societies in the US and Europe adopted an integrated approach to provide information on the clinical benefit (overall survival and progression-free survival) and safety profile of these therapies using the European Society for Medical Oncology (ESMO)–Magnitude of Clinical Benefit Scale (MCBS) score and an ad hoc network meta-analysis. Observations: There is a major consensus among guidelines that atezolizumab plus bevacizumab has a primacy as the recommended first-line treatment of choice in advanced HCC. On progression after immunotherapy-containing regimens and for patients with contraindications for immunotherapies, most guidelines maintain the established treatment hierarchy, recommending lenvatinib or sorafenib as the preferred options, followed by either regorafenib, cabozantinib, or ramucirumab. Thus far, the first-line immune-based regimen of tremelimumab plus durvalumab has been integrated only in the American Association for the Study of Liver Diseases guidance document and the latest National Comprehensive Cancer Network guidelines and has particular utility for patients with a high risk of gastrointestinal bleeding. Overall, in the first-line setting, both atezolizumab plus bevacizumab and sintilimab plus IBI305 (a bevacizumab biosimilar) and durvalumab plus tremelimumab received the highest ESMO-MCBS score of 5, indicating a substantial magnitude of clinical benefit. In a network meta-analysis, no significant differences in overall survival were found among the various combination regimens. However, the newly reported combination of camrelizumab plus rivoceranib was associated with a significantly higher risk of treatment-related adverse events compared with atezolizumab plus bevacizumab (relative risk, 1.59; 95% CI, 1.25-2.03; P < .001). Conclusions and Relevance: This narrative review found that atezolizumab plus bevacizumab is regarded as the primary standard of care for advanced HCC in the first-line setting. These findings from integrating the recommendations from scientific societies’ guidelines for managing advanced HCC along with new data from cross-trial comparisons may aid clinicians in decision-making and guide them through a rapidly evolving and complex treatment landscape.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Over the past two decades, the development of effective systemic therapies has substantially improved the outcomes of patients with advanced-stage HCC2–6.”
From Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma (2024) · cites this paper as [6]
The cited source says what the claim attributes to it.
In the citing paper
“the approval of numerous new systemic agents for advanced-stage HCC has left substantial knowledge gaps in choosing the optimal first-line regimen and the subsequent sequencing of these agents after disease progression6.”
From Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma (2024) · cites this paper as [6]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Assessing the quality of reports of randomized clinical trials: Is blinding necessary?
Jadad, A. R., Moore, R. A., Carroll, D., Jenkinson, C., Reynolds, D. J. M., Gavaghan, D. J., & McQuay, H. J. (1996) · Controlled Clinical Trials · doi:10.1016/0197-2456(95)00134-4 · Cited by 17,582
Sorafenib in advanced hepatocellular carcinoma
Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., de Oliveira, A. C., Santoro, A., Raoul, J.-L., Forner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708857 · Cited by 13,097
Self-citationZhang, Q., Wang, C., Zheng, M., Li, Y., Li, J., Zhang, L., Shang, X., & Yan, C. (2014) · Cerebrovascular Diseases · doi:10.1159/000369778 · Cited by 11,609
Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma
Finn, R. S., Qin, S., Ikeda, M., Galle, P. R., Ducreux, M., Kim, T.-Y., Kudo, M., Breder, V., Merle, P., Kaseb, A. O., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1915745 · Cited by 7,470
Self-citationLlovet, J. M., Kelley, R. K., Villanueva, A., Singal, A. G., Pikarsky, E., Roayaie, S., Lencioni, R., Koike, K., Zucman-Rossi, J., & Finn, R. S. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-00240-3 · Cited by 7,055
Self-citationA New Era of Systemic Therapy for Hepatocellular Carcinoma with Regorafenib and Lenvatinib
Kudo, M. (2017) · Liver Cancer · doi:10.1159/000462153 · Cited by 5,974
Kudo, M., Finn, R. S., Qin, S., Han, K.-H., Ikeda, K., Piscaglia, F., Baron, A., Park, J.-W., Han, G., Jassem, J., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30207-1 · Cited by 5,497
Self-citationEASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma
European Association for the Study of the Liver, & European Organisation for Research and Treatment of Cancer (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2011.12.001 · Cited by 5,218
Dong, Y., Hao, L., Shi, Z., Wang, G., Zhang, Z., & Han, C. (2013) · Urologia Internationalis · doi:10.1159/000351405 · Cited by 4,557
Bruix, J., Qin, S., Merle, P., Granito, A., Huang, Y., Bodoky, G., Pracht, M., Yokosuka, O., Rosmorduc, O., Breder, V. V., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)32453-9 · Cited by 3,725
Self-citation
Research works printed but not linked: 1
- Genentech. Genentech’s Tecentriq plus avastin is the first treatment combination to reduce the risk of cancer returning in people with certain types of early-stage liver cancer in a phase III trial. Press release. January 18, 2023. Accessed February 16, 2023. https://www.gene.com/media/press-releases/14981/2023-01-18/genentechs-tecentriq-plus-avastin-is-the
Cited by
Sorted by citations
Items 101–166 of 166
Huang, Z. J., Zhu, T., Chen, X., Piao, M., Tan, Y., Ct, L., Liu, K., Wang, S., Zhang, L., Du, S., et al. (2026) · BMC Cancer · doi:10.1186/s12885-026-15586-2 · Cited by 1
“Emerging evidence suggests that ICIs, either alone or in combination with TKIs, may reduce recurrence by modulating the tumor immune micro-environment and eradicating residual micro-metastasis [10–12].”
Chen, I.-W., Lin, C.-W., Lin, P., Teng, W., Su, C., Wu, T., Hsieh, Y., Chen, W.-T., Lin, C.-C., Lin, S.-M., et al. (2026) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-026-04308-z · Cited by 1
Ren, G., Cong, Q., Wang, J., Gao, W., Guan, Y., Zhu, L., & Zhu, Y. (2026) · Cancer Science · doi:10.1111/cas.70309 · Cited by 1
Dai, S., Wu, J., Chai, Y., Li, Z., Xie, Y., Wang, H., liu, Z., He, Y., Cao, H. J., Tang, W., et al. (2026) · Cellular Oncology · doi:10.1007/s13402-026-01190-w · Cited by 1
“Consequently, we tested the multi-kinase inhibitor regorafenib, used in advanced liver cancer [47], on CHC organoids.”
Vijay Krishnan, B., kauser, N., Priya, G., & Manjunath, S. M. (2026) · Cureus · doi:10.7759/cureus.106310 · Cited by 1
“Ultimately, 10 studies were excluded due to unmet PICO criteria (e.g., incorrect population, intervention, or outcomes) (Table 3 ) [11-20], while 21 studies met the inclusion criteria (Figure 1 ) [4,21-40].”
Shi, F., Peng, Z., Lian, S., Mai, Q., Xia, D., Li, Q., Wang, M., Chen, S., Mei, J., Han, G., et al. (2026) · Journal of Gastroenterology · doi:10.1007/s00535-026-02406-4 · Cited by 1
“Currently, lenvatinib remains a common choice for first-line treatment in advanced HCC [9].”
Kuo, C., Tai, W., Chen, Y. S., Tsai, M., Wang, J., Lu, S., Hu, T., Hung, C., Chen, C., & Kuo, Y. (2026) · The Kaohsiung Journal of Medical Sciences · doi:10.1002/kjm2.70230 · Cited by 1
Shi, F., Wang, H., Yang, Y., Ding, L., Yi, D., Zhang, Y., Xi, M., Qu, Y., Chen, Z., Lu, Y., et al. (2026) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-25-4502 · Cited by 1
Kou, X.-S., Li, F.-F., Meng, Y., Zhao, J.-M., Liu, S.-F., & Zhang, L. (2024) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v16.i5.2225 · Cited by 1
“Moreover, compared with sorafenib, lenvatinib generally has a superior overall efficacy[23].”
Dispinzieri, G., Becchetti, C., Mazzarelli, C., Airoldi, A., Aprile, F., Cesarini, L., Cucco, M., Perricone, G., Stigliano, R., Vangeli, M., et al. (2024) · Acta gastro-enterologica belgica · doi:10.51821/87.3.13018 · Cited by 1
“A new scenario has opened up in recent years regarding the treatment of HCC with the advent of immunotherapy in hepatology (55).”
Outla, Z., Oyman-Eyrilmez, G., Korelova, K., Přechová, M., Frick, L. D., Sarnová, L., Bisht, P., Novotná, P., Kosla, J., Bortel, P., et al. (2025) · eLife · doi:10.7554/elife.102205.2 · Cited by 1
Editorial: Prediction of Survival in Hepatocellular Cancer—Rise and Fall of the Machines
Pavlides, M. (2026) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.70863 · Cited by 1
“To a great extent, the need for regular updates reflects the changes and the expanding availability of both locoregional and systemic treatment options [3, 4].”
HIMALAYA Overall Survival Prominence and Other Routes to the Peak—Reply
Llovet, J. M., Cappuyns, S., & Finn, R. S. (2024) · JAMA Oncology · doi:10.1001/jamaoncol.2023.6271
Self-citationHIMALAYA Overall Survival Prominence and Other Routes to the Peak
Abou‐Alfa, G. K., & Sangro, B. (2024) · JAMA Oncology · doi:10.1001/jamaoncol.2023.6268
Contemporary Systemic Therapy Approaches for Unresectable Hepatocellular Carcinoma
Lang, D., Agarwal, R., Goff, L. W., & Heumann, T. R. (2024) · Advances in Oncology · doi:10.1016/j.yao.2024.02.001
Kuo, Y., Chen, Y., Tsai, M., Lu, S., Hu, T., Hung, C., Chen, C., & Wang, J. (2024) · Research Square · doi:10.21203/rs.3.rs-4522670/v1
Zhang, J.-X., Yan, H., Fan, W.-L., Wei, J., Liu, S., Shi, H., Cheng, Y., Feng, Z.-L., & Zu, Q. (2024) · Research Square · doi:10.21203/rs.3.rs-5304318/v1
Li, H., Zhang, L., Shu, B., Wang, X., & Yang, S. (2024) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000002894
“In the last 20 years, advancements in systemic therapies have substantially improved the prognosis of patients diagnosed with advanced-stage HCC [4–6 , 40 ].”
Hu, L., Yang, Z., Yang, Z., Peng, W. J., Tang, X., Ye, Z., Wang, J., Fu, Y., Hu, D., Chen, M., et al. (2024) · Hepatology International · doi:10.1007/s12072-024-10757-4
You may delay, but time will not
Kawano, F., & Conrad, C. H. (2025) · Journal of Gastrointestinal Surgery · doi:10.1016/j.gassur.2025.101970
An, J., Li, H., Wen, W., Liu, G., Huang, Z., Zhao, X., & Liang, G. (2025) · SSRN Electronic Journal · doi:10.2139/ssrn.5134742
Current impact in the treatment of advanced hepatocellular carcinoma: The challenge remains
de Mattos, Â. A., Tovo, C. V., Bombassaro, I., & Ferreira, L. F. (2025) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v17.i3.102932
Chen, F., Cai, Y., Chen, X., Chen, C., Fang, Q., Liu, J., Zhang, Y., & Zhou, J. (2025) · Scientific Reports · doi:10.1038/s41598-025-97604-0
Lee, S. K., & Kim, B. H. (2025) · Journal of Digestive Cancer Research · doi:10.52927/jdcr.2025.13.1.65
Novel Immunotherapy for Advanced Hepatocellular Carcinoma
Choi, H.-H., & Yoo, J. (2025) · Korean Journal of Medicine · doi:10.3904/kjm.2025.100.3.102
Shen, X., Shao, T., Yu, J., & Zhang, Z. (2025) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s530550
“9 10–12 This suggests that more effective treatment strategies for PVTT are needed.”
Lee, H.-Y., Chang, C.-D., Chen, Y., Tsai, M., Wang, J., Lu, S., Hu, T., Hung, C., Chen, C., & Kuo, Y. (2025) · Gut and Liver · doi:10.5009/gnl250073
“6 In fact, several real-world studies have demonstrated comparable treat-ment outcomes between lenvatinib and atezolizumab with bevacizumab in the first-line treatment setting.”
Chua, W. Y., Zhao, J. J., Lee, C., Su, Y., Lee, S. Y., Lee, J. J. X., Tai, D. W.-M., Tan, S. H., Sundar, R., & Ng, K. Y. Y. (2025) · SSRN Electronic Journal · doi:10.2139/ssrn.5394949
Ishikawa, T., Sato, R., NATSUI, H., Iwasawa, T., Ogawa, M., Kobayashi, Y., Sato, T., Yokoyama, J., & Honma, T. (2025) · Cancer Diagnosis & Prognosis · doi:10.21873/cdp.10473
Systemic therapies for hepatocellular carcinoma
Cameselle‐García, S., Castro, J. D. F.-D., Álvarez, R. M., & Montes, A. F. (2025) · Revisiones en cáncer · doi:10.20960/revcancer.00102 · Cited by 1
Wang, F., Cao, Z., Yu, C., Li, J., Li, Q., Chang, S., Zhang, S., & Wang, S. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1664519
Villeret, F., Bouattour, M., Blanc, J., Péron, J.-M., Debette‐Gratien, M., Nahon, P., Khac, E. N., Phelip, J., Assénat, E., Bourgeois, V., et al. (2025) · Liver Cancer · doi:10.1159/000549076
Sintilimab Pharmacovigilance in Real-World Practice: Analysis Utilizing the WHO VigiAccess DatabasePreprint
Guo, Y., Wen, L., Jiang, F., Pan, L., He, L., Liu, Z., Wu, Q., Lai, Z., Huang, Q., & Li, Y. (2025) · Research Square · doi:10.21203/rs.3.rs-7907424/v1
Guo, A., Zhang, C., Wen, C., & Wang, X. (2025) · JUSTC · doi:10.52396/justc-2025-0035
Cheng, Z., & Yue, A. (2026) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v18.i1.113816
Narloch, J., Majewska, A., Maciak, M., Brodaczewska, K. K., & Piasecki, P. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27041686
Guo, J., Huang, J., Wang, Y., Sun, J., Liu, S., Deng, C., LÜ, J., & Zhong, Z. (2026) · Acta Biomaterialia · doi:10.1016/j.actbio.2026.03.005
Cho, H. S., & Lee, S. K. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27062680
“Given these high rejection rates, the use of ICIs for recurrent HCC after LT is generally not recommended [88].”
Li, Y., Ren, Y., Li, H., Li, R., You, H., Zhang, Y., Wang, W., Liu, M., Huang, Z., Zhou, Q., et al. (2026) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359261432042
Expert Practical Recommendations for Hepatocellular Carcinoma
Su, F., Torres-Hernandez, A., Hickey, R., Shanbhogue, K., Spencer, K. R., Halazun, K. J., & Villanueva, A. (2026) · Seminars in Liver Disease · doi:10.1055/a-2832-4720
Liu, L., Sheng, Y., Liang, X., Yang, T., Dong, L., Gao, D., Chen, B., Xu, T., Ai, M., Shan, H., et al. (2026) · Clinical Medicine Insights Oncology · doi:10.1177/11795549261434259
“4 Transarterial chemoembolization (TACE) has established itself as a well-validated, effective therapeutic modality for localized malignant hepatic tumors.”
Luo, J., Li, Z., Ge, J., Cai, S., Mo, X., Liu, W., Gui, C., & Du, Q. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1804661
“The goal of systemic therapy is to control disease progression, prolong overall survival (OS), and achieve partial or complete tumor remission in some patients (10).”
Deng, L.-W., Liu, J.-F., Yu, H.-Y., PENG, B., Liu, B., Feng, S.-F., Liu, D., Sun, Y.-Y., Chen, Y., Chen, J., et al. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1748142
Martínez-Artero, B. B., Alimenti, E., Carter, J. K., Pinato, D. J., & Villanueva, A. (2026) · JHEP Reports · doi:10.1016/j.jhepr.2026.101856
“12,13 Thus, there is an urgent need for new tools to enable early-stage HCC detection and the prospective identification of patients who will benefit from systemic therapies.”
Yi, J., Wang, J., Zhang, Y. M., Jiang, X., Chen, S. X., Xu, J., Wu, X., Zhong, S., Chen, Q., Hu, Y., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-73131-y
“However, such long-term responses are rare in advanced HCC patients treated with ICIs-based systemic therapies, with only approximately 0 – 5.5% of patients achieving complete response 35 .”
InfluentialAdvancing Systemic Treatment beyond First Line for Advanced Hepatocellular Carcinoma
Wysocki, P. T., Chmiel, P., Jassem, J., & Kraj, L. (2026) · Current Oncology Reports · doi:10.1007/s11912-026-01792-5 · Cited by 1
Chen, M., Zhang, L., Liu, C., Xu, X., Zhang, J., Yuan, J., Ge, N., Chen, Y., Xie, X., Zhang, L., et al. (2026) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s606458
Lu, H., Xu, T., Li, J., Tang, B., Zeng, Y., Li, X., Cun, J., Xia, X., Hu, J., Xie, X., et al. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1684486
Wang, H., Shi, F., Zhang, X., Zhu, K., Jiang, S., Feng, R., Dou, X., Xu, L., & Yue, J. (2026) · BMJ Open · doi:10.1136/bmjopen-2026-118739
Current advances and future directions in the management of HBV-related hepatocellular carcinoma
Ibrahim, A., Sang, J., Danpanichkul, P., Duangsonk, K., Yang, J. D., Kerr, T. A., & Singal, A. G. (2026) · Gastroenterology report · doi:10.1093/gastro/goag060 · Cited by 1
Sun, R., Tan, H., Wang, Y., Liu, Y.-H., Zhou, X., Feng, H.-G., LIU, H., & Liu, Z. H. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1848104
Artificial intelligence and personalised medicine in liver cancer
Matuschewski, N. J., Baker, W. D., Chapiro, J., & Caldéraro, J. (2026) · Journal of Hepatology · doi:10.1016/j.jhep.2026.04.017 · Cited by 1
Chen, S., Wu, Z., Xiao, Y., Jiang, X., Shi, F., Wang, N., Lin, F., Tan, G., Zhuang, W., & Huang, Y. (2026) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359261472766
“6 Consequently, locoregional approaches have been explored to enhance therapeutic efficacy.”
Wang, Y.-K., Feng, H.-G., Liu, Y.-H., Zhang, C.-Y., Zhou, X., Liu, H.-L., Liu, Z.-J., & Tan, H.-Y. (2026) · Abdominal Radiology · doi:10.1007/s00261-026-05732-6
Karampa, A. D., Goussia, A., Baltagiannis, E. G., Anastasopoulos, N.-A., Christodoulou, D. K., & Glantzounis, G. K. (2026) · Current Oncology · doi:10.3390/curroncol33080492
“ICI combination regimens are now established as the standard of care for advanced HCC. Recent phase III clinical trials are investigating ICI-containing regimens in both resectable and embolization-eligible HCC [32].”
Yu, H., Li, L., Surwase, S. S., Zhou, X. M. M., Qian, H., Sunshine, J. C., Selaru, F. M., & Green, J. J. (2026) · Advanced Science · doi:10.1002/advs.77223
Bispecific antibodies in gastrointestinal cancers: current applications and future perspectives
Ismail, M., Al‐Gizey, N., Al-Najjar, E., Alabed, Z., Mustafa, N., Hamdaneh, Y., & Esmail, A. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1927829 · Cited by 1
“No validated predictive biomarkers currently exist to guide immunotherapy selection in HCC, and optimal treatment sequencing after fi rst-line immunotherapy remains unde fi ned (198, 199).”
Survival trends in distant-stage hepatocellular carcinoma in the United States, 2004–2020Preprint
Hou, J., Wang, C. Y., & Fan, W. (2026) · Research Square · doi:10.21203/rs.3.rs-10626527/v1
Shen, L., Lin, L., Chen, S., Li, C., Tang, R., Xie, L., Wang, Y., Li, Y., Zou, H., Li, D., et al. (2026) · MedComm · doi:10.1002/mco2.70997
“Sintilimab, in combination with bevacizumab, is approved for unresectable hepatocellular carcinoma (HCC), after demonstrating clinical efficacy within the hepatic tumor microenvironment [ 17 ].”
Himoto, T., Fujita, K., & Morishita, A. (2026) · Livers · doi:10.3390/livers6050102
Li, D., Rimassa, L., Ikeda, M., Yarchoan, M. M., Ryoo, B. Y., Koessler, T., Lim, H. Y., Kwiatkowski, M., Chang, T., Kim, J. H., et al. (2026) · Liver Cancer · doi:10.1159/lic/admag013
Self-citationYan, J. J., Meng, L. W., Zeng, Y. Y., Zhang, M. Y., Liu, Q. Q., Zhan, M. J., Yu, H., Liu, Q., Chen, Y., Liao, J., et al. (2026) · Chemical Engineering Journal · doi:10.1016/j.cej.2026.182999
Jain, V., Dar, A. I., Biswas, A., Pulukuri, A. J., Sharma, R., & Sharma, A. (2026) · Biomacromolecules · doi:10.1021/acs.biomac.6c00654
Kunst, C., Schilling, T., Arling, C., Peisl-Gunckel, M., Schlosser‐Hupf, S., Gülow, K., & Müller, M. (2026) · Biomedicines · doi:10.3390/biomedicines14102326
Zhang, C., Yang, Y., Tian, W., Zhang, J., Ge, C., Meng, L., Liu, Y., Wei, Z., & Tian, H. (2026) · Science Advances · doi:10.1126/sciadv.aei7877
“Despite advances in chemotherapy and immunotherapy, the clinical efficacy of current treatment strategies for HCC remains limited, underscoring the need to identify tumor-intrinsic mechanisms that drive therapeutic resistance ( 23 , 24 ).”
Metadata
- Authors
- Cappuyns, S., Corbett, V., Yarchoan, M., Finn, R. S., & Llovet, J. M.
- Affiliations
- Universitair Ziekenhuis Leuven (BE)
- Tisch Cancer Institute (US)
- Johns Hopkins University (US)
- University of California, Los Angeles (US)
- Institució Catalana de Recerca i Estudis Avançats (ES)
- Venue
- JAMA Oncology
- Publisher
- American Medical Association (AMA)
- Published
- 2024-03-01
- Volume
- 10
- Issue
- 3
- Pages
- 395
- ISSN
- 2374-2437 (ISSN-L)
- PMC
- PMC10837331
- OpenAlex
- W4385514156
- Cited by
- 167
- References
- 60
- Citations by year
- 2026: 49 · 2025: 74 · 2024: 41
- FWCI
- 7.18
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- JAMA Oncology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Lirias (KU Leuven) (submittedVersion)
- Funders
- Belgian American Educational Foundation
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- Boston Scientific Corporation
- Exelixis
- Incyte
- Seagen
- Cancer Research UK (C9380/A268-13, A26813, 26813)
- Fundación Científica Asociación Española Contra el Cáncer (C9380/A26813)
- Generalitat de Catalunya (SGR‐1358, PID2019)
- Eisai
- Ministerio de Ciencia e Innovación (PID2019, PID2019-105378RB-I00)
- Associazione Italiana per la Ricerca sul Cancro (A26813, C9380/A26813)
- Vlaamse regering
- Ipsen
- National Institutes of Health (RO1DK56621)
- Genentech
- Agència de Gestió d'Ajuts Universitaris i de Recerca (SGR-1358)
- National Cancer Institute (P50CA062924, R01CA285544)
- National Institute of Diabetes and Digestive and Kidney Diseases (R56DK056621, R01DK056621, R01DK128289)
- Topics
- Health Sciences › Medicine › Hepatology › Hepatocellular Carcinoma Treatment and Prognosis
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Keywords
- advanced hepatocellular carcinoma, systemic therapy, first-line therapy, immune checkpoint inhibitors, atezolizumab plus bevacizumab, lenvatinib, sorafenib, regorafenib, cabozantinib, ramucirumab, angiogenesis inhibitors
- MeSH terms
- Bevacizumab, Sorafenib, Carcinoma, Hepatocellular, Humans, Immunotherapy, Liver Neoplasms, Practice Guidelines as Topic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
